Meeting
2017 ASCO Annual Meeting
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
Authors
Chantale Bernatchez
The University of Texas MD Anderson Cancer Center, Houston, TX
Chantale Bernatchez , Cara L. Haymaker , Michael E. Hurwitz , Harriet M. Kluger , Michael T. Tetzlaff , Natalie Jackson , Ivan Gergel , Mary Ann Tagliaferri , Jonathan Zalevsky , Ute Hoch , Christie Fanton , Ernesto Iacucci , Sandra Aung , Michael Imperiale , Ej Liao , Salah E Bentebibel , Nizar M. Tannir , Patrick Hwu , Mario Sznol , Adi Diab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunoconjugates
Clinical Trial Registration Number
NCT02869295
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2545)
DOI
10.1200/JCO.2017.35.15_suppl.2545
Abstract #
2545
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.
First Author: J. Eva Selfridge
Poster
2017 ASCO Annual Meeting
Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
First Author: Holger N. Lode
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer.
First Author: Takafumi Okayama
First Author: Vuong N. Trieu